公开(公告)号：US20240358751A1

公开(公告)日：2024-10-31

申请号：US18681641

申请日：2022-08-19

申请人： Cedars-Sinai Medical Center

发明人： Vanessa Alexandra Moser ,  Clive Niels Svendsen ,  Helen Goodridge ,  Alexander LaPerle

IPC分类号： A61K35/15 ,  A61P25/28 ,  C12N5/0786

CPC分类号： A61K35/15 ,  A61P25/28 ,  C12N5/0645 ,  C12N2501/115 ,  C12N2501/125 ,  C12N2501/145 ,  C12N2501/15 ,  C12N2501/155 ,  C12N2501/165 ,  C12N2501/22 ,  C12N2501/2303 ,  C12N2501/2334 ,  C12N2501/26 ,  C12N2501/845 ,  C12N2506/45

摘要： Mononuclear phagocytes derived from induced pluripotent stem cells, denoted as iMPs, which comprise monocytes generated from the induced pluripotent stem cells and optionally further macrophages generated from the induced pluripotent stem cells, are provided for use in improving cognitive function, improving neural health, and/or alleviating or treating a neurodegenerative disorder in a mammal In various embodiments, the iMPs produce macrophages after transplantation or after being stimulated in vitro, and/or express macrophage markers. We showed that iMPs upon administration improve cognition and neural healthy in rodent models of aging, Alzheimer's disease, and amyotrophic lateral sclerosis. Treatment methods are also provided using mononuclear phagocytes generated from autologous stem cells or from induced pluripotent stem cells obtained from autologous cells in patients in need of treatment or prophylaxis of a neurodegenerative disorder.

公开(公告)号：US12128070B2

公开(公告)日：2024-10-29

申请号：US17483193

申请日：2021-09-23

申请人： PAEAN BIOTECHNOLOGY INC.

发明人： Kyuboem Han ,  Youngjun Lee

IPC分类号： A61K35/17 ,  A61K9/08 ,  A61K9/19 ,  A61K35/15 ,  A61P35/00 ,  A61P35/02 ,  C12N5/078 ,  C12N5/0783

CPC分类号： A61K35/17 ,  A61K9/08 ,  A61K9/19 ,  A61K35/15 ,  A61P35/00 ,  A61P35/02 ,  C12N5/0634 ,  C12N5/0646

摘要： An NK cells and PBMC, both having increased cytotoxicity are provided. Particularly, NK cells and PBMC which have exogenous mitochondria introduced thereinto potentiate the immune system of the human body to enhance a therapeutic effect on infectious diseases or cancer. Therefore, the NK cells and PBMC can be used in a composition for prevention or treatment of infectious diseases and cancer. Specially, autogenous NK cells and PBMC guarantee stability without the incurrence of an immune reaction, and thus would be expected to have high commercial activity.

公开(公告)号：US20240350540A1

公开(公告)日：2024-10-24

申请号：US18395053

申请日：2023-12-22

申请人： Orbis Health Solutions LLC

发明人： Thomas E. Wagner

IPC分类号： A61K35/15 ,  A61K39/00 ,  C12N5/0784

CPC分类号： A61K35/15 ,  A61K39/0011 ,  C12N5/0639 ,  A61K2039/5154 ,  A61K2039/572

摘要： Dendritic cells containing tumor lysate loaded particles are prepared. The dendritic cells present tumor antigens to elicit the Major Histocompatibility Complex class I pathway and can be used as a vaccine to treat cancer, including ocular melanoma.

公开(公告)号：US20240342211A1

公开(公告)日：2024-10-17

申请号：US18756294

申请日：2024-06-27

申请人： UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION

发明人： Pawel KALINSKI

IPC分类号： A61K35/15 ,  C12N5/0784

CPC分类号： A61K35/15 ,  C12N5/0639 ,  C12N2501/24

摘要： Provided herein are ST-αDC1 and populations of those cells, methods for making ST-αDC1 and populations of those cells, and methods for using ST-αDC1 and populations of those cells for the treatment of cancer, precancerous conditions and chronic infections.

公开(公告)号：US20240293452A1

公开(公告)日：2024-09-05

申请号：US18431638

申请日：2024-02-02

申请人： THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA

发明人： Evgeniy Eruslanov ,  Steven Albelda

IPC分类号： A61K35/15 ,  A61K31/454 ,  A61K38/19 ,  A61K38/21 ,  A61K39/00 ,  A61K39/395 ,  A61K45/06 ,  A61P35/00 ,  C12N5/0787

CPC分类号： A61K35/15 ,  A61K31/454 ,  A61K38/193 ,  A61K38/217 ,  A61K39/0011 ,  A61K39/39541 ,  A61K45/06 ,  A61P35/00 ,  C12N5/0642 ,  A61K2039/5158 ,  A61K2039/572 ,  A61K2039/585 ,  A61K2300/00 ,  C12N2501/22 ,  C12N2501/24 ,  C12N2501/599 ,  C12N2502/30

摘要： The present invention relates to compositions and methods that provide novel anti-tumor therapies in cancer. In one aspect, the present invention features a hybrid neutrophil in a non-naturally occurring container, wherein the hybrid neutrophil expresses at least one neutrophil associated molecule selected from the group consisting of: Arg1, MPO, CD66b, and CD15, and at least one antigen-presenting cell (APC) associated molecule selected from the group consisting of: CD14, HLA-DR, CD32, CD64, and CD89. In another aspect, the present invention features methods of generating a hybrid neutrophil. In still another aspect, the present invention features methods of inhibiting tumor growth in a subject, treating a tumor in a subject, and increasing efficacy of an antibody against a tumor in a subject. The methods comprise (a) administering to the subject an effective amount of an anti-tumor antibody and (b) administering to or generating in the subject an effective amount of a hybrid neutrophil.

公开(公告)号：US12076345B2

公开(公告)日：2024-09-03

申请号：US17827077

申请日：2022-05-27

申请人： Avotres, Inc.

发明人： Hong Jiang

IPC分类号： A61K35/15 ,  A61K31/10 ,  A61K35/17 ,  A61K38/17 ,  A61K38/38 ,  A61K47/20 ,  A61K47/42 ,  A61P17/06 ,  A61P19/02 ,  A61P25/28 ,  A61P37/02 ,  A61P37/04 ,  A61P37/06 ,  C07K14/74 ,  C12N5/0783 ,  C12N5/0784 ,  G01N33/50

CPC分类号： A61K35/17 ,  A61K31/10 ,  A61K35/15 ,  A61K38/1709 ,  A61K38/38 ,  A61K47/20 ,  A61K47/42 ,  A61P17/06 ,  A61P19/02 ,  A61P25/28 ,  A61P37/02 ,  A61P37/04 ,  A61P37/06 ,  C07K14/70539 ,  C12N5/0637 ,  C12N5/0639 ,  G01N33/505 ,  C12N2501/22 ,  C12N2501/2304

摘要： The present invention provides a composition comprising dendritic cells loaded with hHsp60sp, which dendritic cells are from a subject and have been fixed with paraformaldehyde (PFA). The subject may suffer from an autoimmune disease. Also provided are a method for preparing the composition; recombinant human cells comprising a heterologous gene encoding a fusion protein of HLA-E and hHsp60sp or B7sp, and expressing the fusion protein on the surface of the cells; a method for determining a percentage of maximum inhibition of testing the function of the HLA-E restricted CD8+ Treg cells from a subject, determining whether HLA-E restricted CD8+ Treg cells freshly isolated from a subject are defective, or determining whether defective HLA-E restricted CD8+ Treg cells from a subject are correctable; and a method for correcting defective HLA-E restricted CD8+ Treg cells, treating type 1 diabetes (T1D), or treating multiple sclerosis (MS).

公开(公告)号：US12049492B2

公开(公告)日：2024-07-30

申请号：US17399993

申请日：2021-08-11

申请人： Rutgers, The State University of New Jersey

发明人： Dongfang Liu ,  Minh Ma ,  Saiaditya Badeti

IPC分类号： C07K16/10 ,  A61K35/15 ,  A61K35/17 ,  A61K39/00 ,  A61P31/14 ,  C07K14/705 ,  C07K14/715 ,  C07K14/725 ,  C12N9/64

CPC分类号： C07K16/10 ,  A61K35/15 ,  A61K35/17 ,  A61P31/14 ,  C07K14/7051 ,  C07K14/70521 ,  C07K14/7151 ,  C12N9/6472 ,  C12Y304/22062 ,  A61K39/00 ,  C07K2317/24 ,  C07K2317/53 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2319/03 ,  C07K2319/33

摘要： Chimeric antigen receptors (CARs) including an antigen binding domain specifically binding to coronavirus spike protein, nucleic acids encoding the CARs, vectors including nucleic acids encoding the CARs, and immune cells expressing the CARs are provided. Methods of treating a subject with coronavirus, including administering to the subject an immune cell expressing a disclosed CAR are also provided.

公开(公告)号：US12043823B2

公开(公告)日：2024-07-23

申请号：US17702658

申请日：2022-03-23

申请人： Terumo BCT, Inc.

发明人： Mark E. Jones ,  Dalip Sethi ,  Dennis J. Hlavinka ,  Thomas J. Felt

IPC分类号： C12M1/12 ,  A61K35/15 ,  C12M1/10 ,  C12M3/00 ,  C12N5/00 ,  C12N5/0789

CPC分类号： C12M25/10 ,  A61K35/15 ,  C12M1/10 ,  C12M3/00 ,  C12N5/0068 ,  C12N5/0647 ,  C12N2501/125 ,  C12N2501/145 ,  C12N2501/26 ,  C12N2502/1358 ,  C12N2533/52

摘要： Implementations are described that relate to methods and systems for growing cells in a hollow fiber bioreactor. In implementations, the cells may be exposed to a number of growth factors including a combination of recombinant growth factors. In other implementations, the cells may be grown in co-culture with other cells, e.g., hMSC's. In implementations, the cells may include CD34+ cells. A coated membrane includes a membrane having a first coating configured to promote cellular adhesion to the membrane and a second coating that includes a soluble protein moiety.

公开(公告)号：US20240238338A1

公开(公告)日：2024-07-18

申请号：US18560263

申请日：2022-05-10

申请人： Washington University

发明人： Jonathan Kipnis

IPC分类号： A61K35/15 ,  A61P25/00

CPC分类号： A61K35/15 ,  A61P25/00

摘要： Compositions and methods for the treatment, prevention, or reversal of a central nervous system (CNS) injury or disorder in a patient in need that include administering a therapeutically effective amount of meningeal immune cells are disclosed. Specifically, the meningeal immune cells comprise Ly6C+ monocytes. Further disclosed are wherein the meningeal immune cells are modified to include a drug or gene therapeutic compound, and wherein the modified meningeal immune cells are configured to deliver the drug or gene therapeutic compound to the CNS of the subject via the parenchyma or meningeal tissue of the subject.

公开(公告)号：US20240216426A1

公开(公告)日：2024-07-04

申请号：US18557559

申请日：2022-04-27

申请人： TAKEDA PHARMACEUTICAL COMPANY LIMITED

发明人： Nandhu SOBHANA ,  Alisha BOTHUN ,  Gil BENEZER ,  Shruti BADKAR ,  Rabi MISHRA ,  Hui-Hsin CHANG ,  Wanwen LI ,  Mansi SONI ,  Lan CAO ,  Xi SHl ,  Jane YEH ,  Mengyao LUO ,  Manoj GUPTA ,  Akito NAKAMURA ,  Doanh MAI ,  Mei Rosa NG

IPC分类号： A61K35/15 ,  A61K39/00 ,  C07K14/54 ,  C07K14/705

CPC分类号： A61K35/15 ,  A61K39/463 ,  C07K14/54 ,  C07K14/5443 ,  C07K14/70575 ,  C07K2319/03 ,  C07K2319/30 ,  C12N2501/2315 ,  C12N2501/2321 ,  C12N2506/45 ,  C12N2510/00

摘要： The present disclosure provides recombinant antigen presenting cells and methods of use thereof in the culture and expansion of immune cells ex vivo. In some aspects, immune cells expanded through co-culture of the recombinant antigen presenting cells disclosed herein are administered to a subject to treat a disease or condition in the subject, e.g., to treat a cancer.